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Protein tyrosine phosphatase 1B (PTP1B) inhibits insulin signaling and, when overexpressed, plays a role in insulin
resistance (Ahmad et al. 1997). We identified, in the 3′ untranslated region of the PTP1B gene, a 1484insG variation
that, in two different populations, is associated with several features of insulin resistance: among male individuals,
higher values of the insulin resistance HOMAIR index ( ), serum triglycerides ( ), and total/HDLPp .006 Pp .0002
cholesterol ratio ( ) and, among female individuals, higher blood pressure ( ). Similar data werePp .025 Pp .01
also obtained in a family-based association study by use of sib pairs discordant for genotype (Gu et al. 2000).
Subjects carrying the 1484insG variant showed also PTP1B mRNA overexpression in skeletal muscle (6,166 
1,879 copies/40 ng RNA vs. 2,983  1,620; ). Finally, PTP1B mRNA stability was significantly higherP ! .01
( ) in human embryo kidney 293 cells transfected with 1484insG PTP1B, as compared with those transfectedP ! .01
with wild-type PTP1B. Our data indicate that the 1484insG allele causes PTP1B overexpression and plays a role
in insulin resistance. Therefore, individuals carrying the 1484insG variant might particularly benefit from PTP1B
inhibitors, a promising new tool for treatment of insulin resistance (Kennedy and Ramachandran 2000).
The insulin resistance/metabolic syndrome—character-
ized by the variable coexistence of hyperinsulinemia, dis-
lipidemia, obesity, and hypertension—is influenced by
both environmental and genetic background, the latter
being mostly unknown (Trischitta et al. 1997; Virkamaki
et al. 1999). Protein tyrosine phosphatase 1B (PTP1B)
is a major regulator of insulin sensitivity and body fat
(Ahmad et al. 1995; Kenner et al. 1996; Ahmad et al.
1997; Elchebly et al. 1999; Goldstein et al. 2000; Kla-
man et al. 2000). In fact, PTP1B directly interacts with
and dephosphorylates the activated insulin receptor
(Seely et al. 1996; Bandyopaddhyay et al. 1997), thus
inhibiting insulin signaling and action. In addition, type
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2 diabetes and obesity have been linked to markers on
human chromosome 20q13.1 (Lembertas et al. 1997;
Lee et al. 1999; Klupa et al. 2000), which harbors
PTP1B. Also, the mouse PTP1B region (i.e., the distal
arm of chromosome 2, syntenic with human chromo-
some 20) is likely to harbor a gene for obesity (Lembertas
et al. 1997). These data indicate that PTP1B is a can-
didate gene for insulin resistance/metabolic syndrome.
We searched for polymorphisms in both the regulatory
and coding regions of the human PTP1B gene (Forsell
et al. 2000). Table 1 shows the primer sets used for the
screening by PCR and SSCP. Because of an alternative
splicing in intron 9, two different 3′ UTRs are transcribed
for PTP1B (Forsell et al. 2000). Both 3′ UTRs were
screened. Samples carrying different electrophoretic pat-
terns were automatically sequenced after cloning (at least
five clones) in pCR II TOPO vector (Invitrogen).
Several single-nucleotide polymorphisms (SNPs) were
identified in 100 unrelated subjects from the Gargano
area (on the east coast of central Italy) (table 2). Because
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Table 1
Primers and PCR Conditions
Exon Primers
Annealing
Temperature
(C)
Amplimer Size
(bp)
PR1 (594/431) Forward: 5′-TGCAGCACCCAAGTGGAAATTC-3′ 60 229
Reverse: 5′-TCATGCACCTCCTTTCCTGCAG-3′
PR2 (510/215) Forward: 5′-TGATACTCCTGAGTTTCAT-3′ 58 338
Reverse: 5′-AGCACCGCGAGATATCTAATAGC-3′
PR3 (261/55) Forward: 5′-GTCGCCTAGGCAACAGGCGCG-3′ 60 262
Reverse: 5′-TAGCCGCTGCTCTTCTTCATG-3′
PR4 (68/108) Forward: 5′-GCAGGCGTGATGCGTAGTTC-3′ 60 218
Reverse: 5′-GACTTGTCGATCTGCTCGAA-3
Exon 1 Forward: 5′-CTGGCAGGCGTGATGCGTAG- 3′ 68 300
Reverse: 5′-GATGTTCAAGCGGCCTAAGCG-3′
Exon 2 Forward: 5′-GTCTTCCTCAGTGTCTGACGGTC-3′ 68 192
Reverse: 5′-GCCTGCAGCAAAGGAAGAGC-3′
Exon 3 Forward: 5′-TGTACACATTCAGCTTTTCC-3′ 58 226
Reverse: 5′-TGAGGTGTGGATAACAGC-3′
Exon 4 Forward: 5′-TCGTTAGCTGACTGCAGAAGG-3′ 60 244
Reverse: 5′-ATGGTAACTATATGGAGTGG-3′
Exon 5 Forward: 5′-TCATGAAGCTTGTGGGATGTGC-3′ 60 316
Reverse: 5′-TGACATTAGGTAATATCACC-3′
Exon 6 Forward: 5′-GAAGGTGACTCTGTGTGTAC-3′ 64 349
Reverse: 5′-TCACAGCAGAGCAGGTAGAGGAGC-3′
Exon 7 Forward: 5′-TGAGAATTGGACCTGGC-3′ 62 283
Reverse: 5′-TACAACTGACAGCCTCCTTC-3′
Exon 8 Forward: 5′-TGACAAACCAGCCGAAGTGAAC-3′ 62 354
Reverse: 5′-TCAGTACCAGCGTGTGTTTC-3′
Exon 9 Forward: 5′-GAGTACCCATCTCTGCCCTCTG-3′ 62 324
Reverse: 5′-CAGATGCACCACAGAACTGAATCC-3′
Exon 10a Forward: 5′-CATGAGGCGACAGCACTGC-3′ 62 350
Reverse: 5′-CTTCCATTCCCAGTACTACCTGA-3′
3′ UTR A Forward: 5′-AGGACGGTTGTAAGCAGTTGTT-3′ 62 329
Reverse: 5′-GGAACCACAGCCAGTTTATGAT-3′
3′ UTR B Forward: 5′-TCTCTGCTTACTAATGTGCCCC-3′ 60 351
Reverse: 5′-TCAAGAGTGTCGACTTGGA-3′
3′ UTR C Forward: 5′-TCTGGACATGATTTAGGGAAGC-3′ 62 320
Reverse: 5′-TGCCGTGTTTTTCATGTTAAAA-3′
3′ UTR D Forward: 5′-AAAGGGAACTGAAGACCTCCAC-3′ 64 314
Reverse: 5′-GGAGGTTAAACCAGTACGTCCA-3′
3′ UTR E Forward: 5′-ATTCTGAGCTGGCTTGTTGTTT-3′ 62 234
Reverse: 5′-GGTTTATTCCATGGCCATTGTA-3′
Intron 9 A Forward: 5′-CTGGTCAACATGTGCGTGG-3′ 62 267
Reverse: 5′-CTTGGGACCAGAGGGCTC-3′
Intron 9 B Forward: 5′-TTAAGGATCGATGCACTGGG-3′ 62 324
Reverse: 5′-TTGGGATTCCTTCCCTGGG-3′
Intron 9 C Forward: 5′-CCTTAGGTGATGTAATCAGCC-3′ 62 350
Reverse: 5′-AGGCCTCGAGGACACCC-3′
Intron 9 D Forward: 5′-CCTGTGACAGCCATCTTGC-3′ 62 327
Reverse: 5′-CATCTGATGTACTCAGATGCC-3′
Intron 9 E Forward: 5′-ACTAGCCTCAGAGCTCTGG-3′ 58 348
Reverse: 5′-GTGGAGGTGGAGTGGAGG-3′
a Proximal region of the 3′ UTR.
of a low allele frequency (AF) (i.e., !2%) and/or the
nature of sequence variations (i.e., either silent or in-
tronic), only the SNP localized in the 3′ UTR (1484insG
SNP, according to the published sequence [GenBank ac-
cession number M33689]) was considered for associa-
tion studies with insulin resistance/metabolic syndrome.
For this purpose, RFLP analysis was used, because a
SacII restriction site was created by 1484insG.
To minimize the inclusion of genetic determinants of
b-cell failure, rather than insulin resistance, and to avoid
the confounding effect of hyperglycemia on insulin-
resistance–related abnormalities, we analyzed only non-
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Table 2
SNPs in the PTP1B Gene
Designation Location Type
Restriction
Enzyme
AF
(%)
105delA 5′ UTR Noncoding … 1
A669G Exon 6 Synonymous … 3
C981T Exon 8 Synonymous … 7
C1207T Exon 9 Missensea … .9
delT Intron 3 … 1.1
A/C Intron 5 50
1484insG 3′ UTR Noncoding SacII 7.7
1737insG 3′ UTR Noncoding … 1.9
T2251C 3′ UTR Noncoding … 1
A2261G 3′ UTR Noncoding … 1
a Leu379Phe.
Table 3
Clinical Features of Subjects from the Two Different Populations Pooled Together
FEATURE
MEAN  SEM VALUES FOR SUBJECTS
Male Female
Wild Type
( [90%])np 302
1484insG
( [10%])np 33
Wild Type
( [84%])np 401
1484insG
( [16%])np 76
Age (years) 38.2  .7 38.1  1.8 36.7  .6 39.8  1.3a
BMI (kg/m2) 28.2  .4 29.4  1.3 26.5  .3 25.7  .7
Fasting plasma glucose (mg/dl) 91.6  .6 93.4  1.3 88.7  .5 88.9  .9
Fasting plasma insulin (mU/l) 9.2  .3 12.5  1.8b 8.9  .3 8.1  .6
HOMAIR 2.1  .1 3.0  .5
b 2.0  .1 1.8  .1
Fasting serum cholesterol:fasting
serum HDL cholesterol ratio 4.6  .1 5.2  .3a 3.7  .1 3.7  .1
Fasting serum triglycerides (mg/dl) 118.0  4.0 169.8  20.3c 83.7  2.6 87.2  5.1
Systolic blood pressure (mm Hg) 119.1  .7 117.6  1.9 111.1  .6 114.2  1.5a
Diastolic blood pressure (mm Hg) 78.7  .5 76.7  1.1 73.0  .4 75.7  .8b
NOTE.—All differences—except fasting serum cholesterol/fasting serum HDL cholesterol, in male subjects, and
systolic blood pressure, in female subjects—remained significant after correction for multiple comparisons.
a versus wild type.P ! .05
b versus wild type.P ! .01
c versus wild type.P ! .001
diabetic subjects. First, 477 normoglycemic (fasting
plasma glucose !126 mg/dl), unrelated white subjects
from the Gargano area were studied. Also, 335 normo-
glycemic individuals from Sicily were analyzed, to repli-
cate the association study. In all subjects, the following
parameters were assessed: BMI; waist and hip circumfer-
ence; blood pressure; and fasting glucose, insulin, and
lipid profiles. Plasma glucose (mmol/l), serum insulin
(pmol/l), and lipid profile (total serum cholesterol, HDL
cholesterol, and serum triglycerides) were measured by
use of commercially available enzymatic kits, as described
elsewhere (De Cosmo et al. 1997). The insulin-resistance
index HOMAIR (homeostasis model assessment) was cal-
culated as fasting serum insulin (mU/ml)# fasting plasma
glucose (mmol/l)/22.5 (Bonora et al. 2000). In individuals
from Sicily, glucose and insulin levels were also measured
before, 60 min after, and 120 min after a 75-g oral-glucose
load was given. Values are given as mean  SEM. Mean
values of unrelated individuals from the two genotype
groups were compared by Student t-test or Mann-Whit-
ney U test, as appropriate. Informed consent was obtained
from participants before they entered the study, which
was approved by the local research ethics committee.
Among the 477 unrelated individuals from the Gargano
region (165 male subjects, aged 37.9  0.9 years, and
312 female subjects, aged 38.2  0.6 years; 1484insG
AF 7.7%, in Hardy-Weinberg equilibrium), male subjects
carrying the 1484insG allele ( ) showed, comparednp 15
with wild-type individuals, higher BMI values (29.2 
1.1 kg/m2 vs. 25.7  0.3; ), fasting plasma in-Pp .001
sulin (10.0  1.1 mU/L vs. 7.8  0.3; ), serumPp .048
triglycerides (168  39 mg/dl vs. 118  6; ),Pp .034
total/HDL cholesterol ratio (5.2  0.4 vs. 4.4  0.1;
) and the insulin-resistance HOMAIR indexPp .035
(Bonora et al. 2000) (2.4  0.3 vs. 1.7  0.1; Pp
). Female subjects carrying the 1484insG allele.025
( , including 3 homozygous subjects) showednp 56
higher values of systolic (114  1.6 mm Hg vs. 110 
0.7; ) and diastolic (75  0.9 mm Hg vs. 73Pp .024
 0.5; ) blood pressure but not of other insulin-Pp .038
resistance–related parameters. As mentioned above, 335
nondiabetic Sicilians (170 male subjects, aged 38.5 0.9
years, and 165 female subjects, aged 35.2  0.9 years;
1484insG AF 5.2%) were studied, to replicate the data
in a population that, although geographically close to the
first population, is known to be of different ethnicity (Pi-
azza et al. 1988). This would minimize the risk of false-
positive results due to “population stratification” (Al-
tshuler et al. 1998; “Freely Associating” 1999). Male
subjects carrying the 1484insG allele ( , includingnp 18
1 homozygous subject) showed higher levels of fasting
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Figure 1 Glucose (A and C) and insulin (B and D) plasma levels before (time 0), 60 min after, and 120 min after a 75-g oral-glucose
load was given to 170 male subjects (A and B) and 165 female subjects (C and D) from Sicily. Blackened circles indicate subjects carrying the
1484insG. Unblackened circles indicate subjects not carrying the 1484insG. Data are mean  SEM. An asterisk (*) denotes a P value !.01,
by two-way ANOVA, versus subjects not carrying 1484insG. A pound sign (#) denotes a P value !.05, by two-way ANOVA, versus subjects
not carrying 1484insG.
plasma insulin (14.6  3.1 mU/L vs. 10.6  0.6; Pp
) and serum triglycerides (171  19 mg/dl vs..041
1185; ) as compared to individuals carryingPp .001
the wild-type genotype. No difference between the two
groups was observed in BMI, HOMAIR index, or total/
HDL cholesterol ratio. Also, no difference in any of the
above-mentioned variables was observed between female
subjects carrying the 1484insG allele ( ) and thosenp 20
not carrying that allele. In this second population, glucose
and insulin levels during oral-glucose–tolerance test
(OGTT) were also available. Although glucose levels were
similar between the two genotype groups (fig. 1A and
1C), insulin levels during OGTT were higher both in male
subjects ( , by two-way analysis of variancePp .005
[ANOVA]) and, to a lesser extent ( ), in femalePp .024
subjects carrying the 1484insG allele, as compared with
wild-type individuals (fig. 1B and 1D) (i.e., compensatory
hyperinsulinemia, a typical feature of insulin resistance in
normoglycemic individuals). Then the two populations
were pooled and were examined together (table 3). Male
subjects carrying the 1484insG allele ( [10%]) hadnp 33
higher values of insulin resistance HOMAIR index (Pp
), total/HDL cholesterol ratio ( ), and serum.006 Pp .025
triglycerides ( ) and had a 3.5-fold (95% CIPp .0002
1.64–7.47) higher ( ) risk to show a cluster ofPp .001
insulin-resistance–related metabolic abnormalities (i.e.,
values in two or three of the three above-mentioned pa-
rameters were in the highest quartile of the entire cohort).
Female subjects carrying the 1484insG allele (np 76
[16%]) had higher systolic ( ) and diastolicPp .03
( ) blood pressure, the latter parameter remain-Pp .007
ing significantly ( ) different also when adjustedPp .01
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Figure 2 A, left, specific mRNA content (by competitive PCR before and after transcription inhibition for 40 h with 5 mg/ml actinomycin
D) in human embryo kidney 293 cells transfected with either wild-type (white columns) or 1484insG (black columns) cDNA. A, right, data
from the left panel are recalculated as % decrease after treatment with actinomycin D. Data are mean SEM of the results of three independent
experiments. B, Representative competitive PCR for both wild-type (wt) and 1484insG transfected cells.
(by analysis of covariance) for the slightly different ob-
served age (table 3). The proportion of individuals car-
rying the 1484insG allele was higher ( , by x2 test)Pp .02
in female subjects (16%) than in male subjects (10%)
(table 3). This may be the consequence of the apparently
stronger association between the 1484insG allele and in-
sulin resistance observed in male subjects than is observed
in female subjects. One could, in fact, speculate that male
1484insG carriers are more likely to have been removed
from the cohort of normoglycemic subjects we recruited,
because of a more rapid progression to type 2 diabetes
and/or early mortality for cardiovascular disease—both
events being possible outcomes of insulin resistance/met-
abolic syndrome. To further minimize the risk of popu-
lation-stratification bias, sib pairs concordant for sex and
discordant for genotype from the Gargano region were
also studied. Of 181 sib pairs concordant for sex, 13 were
discordant for the PTP1B genotype. The differences in
continuous variables between the siblings were estimated
by use of a permutation test for paired replicates, as de-
scribed elsewhere (Gu et al. 2000). The permutation test
does not make any assumptions about the normality, the
homogeneity of the variance, or the precise form of the
underlying distribution. In the permutation test for 13
pairs, there are 213 equally likely outcomes for each var-
iable, under the assumption of no difference between the
paired siblings. Because of computational limitations, the
two-tailed P values were estimated by use of a very large
(107) random sample from all possible permutations. If
the observed sum of differences (OSD) entered the 5%
region of rejection, the differences between pairs was con-
sidered significant. The differences in phenotypic values
were computed as the value in the sibling with the
1484insG variant minus the value in the sibling with the
wild-type genotype. Sibs carrying the 1484insG allele
showed higher BMI, total/HDL cholesterol ratio, triglyc-
erides, and diastolic blood pressure (table 4). All together,
these data show that the 1484insG variant of the PTP1B
gene 3′ UTR associates with several features of insulin
resistance/metabolic syndrome. This association seems to
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Table 4
Clinical Features of 13 Sib Pairs Discordant for the PTP1B Genotype
FEATURE
MEAN  SEM VALUES
FOR SIBS
OSD PaWild Type 1484insG
Age (years) 35.7  2.6 36.1  2.9 22.0 NS
BMI (kg/m2) 23.7  .88 26.3  1.14 34.2 .02
Fasting plasma glucose (mg/dl) 88.2  1.16 88.2  1.9 .50 NS
Fasting plasma insulin (mU/L) 7.5  1.0 7.8  .7 4.45 NS
HOMAIR 1.63  .2 1.72  .2 1.07 NS
Fasting serum cholesterol:fasting
serum HDL cholesterol ratio 3.5  .3 4.35  .4 11.3 .02
Fasting serum triglycerides (mg/dl) 92.4  14.5 116.6  16.6 315.0 .03
Systolic blood pressure (mm Hg) 109.6  4.2 113.4  4.5 50.0 NS
Diastolic blood pressure (mm Hg) 73.3  2.5 77.1  2.8 50.0 .05
a NS p not significant.
be stronger among male subjects than among female sub-
jects. This is not surprising, because a sex-specific effect
of PTP1B (Klaman et al. 2000) and other insulin-resis-
tance genes (Bruning et al. 2000) has been reported in
animal models. In several instances, the 3′ UTRs may
regulate gene expression through the modulation of
mRNA stability (Day and Tuite 1998; Xia et al. 1998;
Frittitta et al. 2001). Accordingly, PTP1B mRNA levels
were measured in skeletal-muscle specimens by compet-
itive PCR, as described elsewhere (Frittitta et al. 2000).
For this purpose, a competitor was created. A PTP1B
cDNA portion containing nt 662–1251, according to the
published sequence (GenBank accession number
M33689), was amplified from the pAD.CMVPTP1B plas-
mid. An internal EarI fragment (nt 931–1073) was re-
moved and the deleted cDNA, cloned in pCR II TOPO
vector (Invitrogen), was used as the competitor. Constant
amounts of PTP1B reverse-transcription first-strand
products were coamplified with increasing copy-number
amounts of competitor, and the equivalence point was
determined after PCR and electrophoretic analysis.
To assess the reproducibility of competitive PCR, sam-
ples were analyzed in triplicate, with a mean coefficient
of variation of 15%. PTP1B mRNA levels were higher
in five muscle samples from 1484insG carriers than in
11 age- and sex-matched wild-type individuals (6,166
 1,879 copies/40 ng RNA vs. 2983  1620; ).P ! .01
To investigate whether the 1484insG variation may be
responsible for changes inPTP1BmRNA stability, human
embryo kidney 293 cells were transiently transfected
(Chen and Okayama 1987) with either 1484insG or wild-
type cDNA. Specific PTP1B mRNA level (by competitive
PCR) before and after 40 h of 5 mg/ml actinomycin D
pre-exposure (i.e., inhibition of transcription) was then
measured. The decrease of mRNA level after transcription
inhibition was significantly ( ) lower for 1484insGP ! .01
PTP1B transfected cells as compared to wild-type PTP1B
transfected cells (fig. 2). This indicates that the G insertion
at position 1484 stabilizes PTP1B mRNA. The 3′ UTR
sequence has an essential role for the regulation of mRNA
stability, and variants in this region have been associated
with insulin resistance (Xia et al. 1998; Maegawa et al.
1999). The 3′ UTR may regulate mRNA stability through
the binding with specific proteins, which occurs mostly
but not exclusively at AU-rich regions (Conne et al. 2000;
Day and Tuite 1998). The 3′ UTR of the PTP1B gene
does not contain adenylate/uridylate–rich elements.
Therefore, the 1484insG variation is likely to play a role
in PTP1B mRNA stability through the modulation of
protein binding to not-yet-identified 3′ UTR elements.
In conclusion, the 1484insG variation increasesPTP1B
mRNA stability and associates with several features of
insulin resistance/metabolic syndrome. This association
has been validated (Altshuler et al. 1998; “Freely Asso-
ciating” 1999) by replication of data in unrelated indi-
viduals of different ethnicity and in a family-based study.
Screening for the 1484insG variation may, therefore,
identify those subjects in whom PTP1B overexpression
can be recognized as a molecular cause of insulin resis-
tance. These individuals might particularly benefit from
PTP1B inhibitors, a promising new tool for treatment of
insulin resistance (Kennedy and Ramachandran 2000).
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